Paper39101697
Etiologies of Persistent Aminotransferase Elevations in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogs.
Xiong QF and 6 others. Turk J Gastroenterol, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Etiologies of Persistent Aminotransferase Elevations in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogs. Papers, record 39101697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39101697
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Etiologies of Persistent Aminotransferase Elevations in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogs.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B, Chronic | Major topic |
| Antiviral Agents | Major topic |
| Viral Load | Major topic |
| Alanine Transaminase | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Adult | |
| Retrospective Studies | |
| Aged | |
| Young Adult | |
| Hepatitis B virus | |
| Liver | |
| Non-alcoholic Fatty Liver Disease | |
| Nucleosides |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26563120 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. | Hepatol Int | 2016 | https://conductscience.org/library/papers/26563120 | PubMed |
| 2 | 16979376 | Regulatory failure of serum prohepcidin levels in patients with hepatitis C. | Hepatol Res | 2006 | https://conductscience.org/library/papers/16979376 | PubMed |
| 3 | 33404182 | Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. | Liver Int | 2021 | https://conductscience.org/library/papers/33404182 | PubMed |
| 4 | 25677884 | Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. | Hepatology | 2015 | https://conductscience.org/library/papers/25677884 | PubMed |
| 5 | 30926241 | EASL Clinical Practice Guidelines: Drug-induced liver injury. | J Hepatol | 2019 | https://conductscience.org/library/papers/30926241 | PubMed |
| 6 | 18694399 | Occult hepatitis B virus infection in patients with autoimmune liver diseases. | Liver Int | 2009 | https://conductscience.org/library/papers/18694399 | PubMed |
| 7 | 28052621 | Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). | Liver Int | 2017 | https://conductscience.org/library/papers/28052621 | PubMed |
| 8 | 35373500 | Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. | Liver Int | 2022 | https://conductscience.org/library/papers/35373500 | PubMed |
| 9 | 28480063 | Viral hepatitis and hepatocellular carcinoma: etiology and management. | J Gastrointest Oncol | 2017 | https://conductscience.org/library/papers/28480063 | PubMed |
| 10 | 15915461 | Design and validation of a histological scoring system for nonalcoholic fatty liver disease. | Hepatology | 2005 | https://conductscience.org/library/papers/15915461 | PubMed |
| 11 | 33962041 | Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. | Clin Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/33962041 | PubMed |
| 12 | 17628332 | Diagnosis and management of cholestatic liver disease. | Clin Gastroenterol Hepatol | 2007 | https://conductscience.org/library/papers/17628332 | PubMed |
| 13 | 32077604 | Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. | Liver Int | 2020 | https://conductscience.org/library/papers/32077604 | PubMed |
| 14 | 28052622 | Novel targets for hepatitis B virus therapy. | Liver Int | 2017 | https://conductscience.org/library/papers/28052622 | PubMed |
| 15 | 26516032 | EASL Clinical Practice Guidelines: Vascular diseases of the liver. | J Hepatol | 2016 | https://conductscience.org/library/papers/26516032 | PubMed |
| 16 | 25595883 | Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. | J Hepatol | 2015 | https://conductscience.org/library/papers/25595883 | PubMed |
| 17 | 35662478 | EASL Clinical Practice Guidelines on haemochromatosis. | J Hepatol | 2022 | https://conductscience.org/library/papers/35662478 | PubMed |
| 18 | 27981592 | The ascending pathophysiology of cholestatic liver disease. | Hepatology | 2017 | https://conductscience.org/library/papers/27981592 | PubMed |
| 19 | 35229330 | Cholestatic liver diseases of genetic etiology: Advances and controversies. | Hepatology | 2022 | https://conductscience.org/library/papers/35229330 | PubMed |
| 20 | 34557660 | Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. | JHEP Rep | 2021 | https://conductscience.org/library/papers/34557660 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42942523 | Why Outcomes Diverge in Chronic Hepatitis B with Steatotic Liver Disease: Lessons from Within-Study Contrasts. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42942523 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39101697
GET https://conductscience.org/api/papers/v1/39101697/references?page=2